These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 9032578)

  • 1. New directions in cyclooxygenase research and their implications for NSAID-gastropathy.
    Flower RJ
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():23-7. PubMed ID: 9032578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New NSAIDs and gastroduodenal damage.
    Folco GC
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():28-9. PubMed ID: 9032579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Preferential COX-2 inhibition: its clinical relevance for gastrointestinal non-steroidal anti-inflammatory rheumatic drug toxicity].
    Dammann HG
    Z Gastroenterol; 1999 Jan; 37(1):45-58. PubMed ID: 10091284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Mechanism of inhibition OF COX-2 and COX-3 in gastrointestinal damage induced by NSAID in rats ].
    Laudanno OM; San Miguel P; Aramberry LJ; Cesolari JA
    Acta Gastroenterol Latinoam; 2003; 33(4):183-5. PubMed ID: 14708469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Specific COX-2 inhibitors: prospects of therapy with new analgesic and anti-inflammatory substances].
    Hinz B; Brune K
    Wien Klin Wochenschr; 1999 Feb; 111(3):103-12. PubMed ID: 10093892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Non-steroidal antiinflammatory drug--management of gastrointestinal complications and inhibition of COX-2].
    Tada Y; Nagasawa K
    Nihon Rinsho; 1999 Feb; 57(2):419-24. PubMed ID: 10078017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2 selectivity in gastroenterology].
    Ledro Cano D; Gómez Rodríguez BJ; Torres Domínguez Y; Hergueta Delgado P; Herrerías Esteban JM; Herrerías Gutiérrez JM
    Rev Esp Enferm Dig; 1999 Apr; 91(4):305-9. PubMed ID: 10348929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COX-1 and COX-2 inhibition: current status and future perspective.
    Greyn J; Lauwers MH; Vanlersberghe C; Camu F
    Acta Anaesthesiol Belg; 1998; 49(3):175-83. PubMed ID: 9844704
    [No Abstract]   [Full Text] [Related]  

  • 10. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D; Percival MD; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Falgueyret JP; Ford-Hutchinson AW; Gordon R; Greig G; Gresser M; Guay J; Kargman S; Léger S; Mancini JA; O'Neill G; Ouellet M; Rodger IW; Thérien M; Wang Z; Webb JK; Wong E; Chan CC
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Coxibs: cyclooxygenase-2 inhibitors].
    Turnheim K
    Wien Klin Wochenschr; 2001 Aug; 113(15-16):558-65. PubMed ID: 11571832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New NSAIDS: COX-1, COX-2, what about them?].
    Peretz A
    Rev Med Brux; 1998 Sep; 19(4):A399-402. PubMed ID: 9805982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scientific rationale for specific inhibition of COX-2.
    Bolten WW
    J Rheumatol Suppl; 1998 May; 51():2-7. PubMed ID: 9596548
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do non-steroidal anti-inflammatory drugs and COX-2 selective inhibitors have different renal effects?
    Giovanni G; Giovanni P
    J Nephrol; 2002; 15(5):480-8. PubMed ID: 12455713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 inhibitors. What is their place?
    McGettigan P
    Aust Fam Physician; 2000 Sep; 29(9):847-52. PubMed ID: 11008387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The multisystem adverse effects of NSAID therapy.
    James DS
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S1-7. PubMed ID: 10643174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
    van der Bijl P; van der Bijl P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.